Innovation in QT Strategies: Leveraging Early-stage Safety Methodologies and AI to Maximize Your Opportunity for a TQT Waiver Webinar Replay

Discover the groundbreaking advancements in drug development with our latest webinar, now available on demand! Delve into the challenges and solutions surrounding the low success rate of new drugs, particularly the 70% failure rate during Phase I trials due to unmanageable toxicity or poor pharmacokinetics.

Learn how early and accurate cardiac safety assessments, specifically focusing on the QT interval, are critical for making informed decisions that can determine the future of a drug candidate. Our expert speakers explain how the innovative Expert Precision QT (EPQT) methodology, developed in collaboration with the FDA, ensures high-precision QT interval measurement using the advanced iCOMPAS technology. This approach provides invaluable cardiac safety data during single and multiple ascending dose studies in Phase I, offering potential waivers for Thorough QT (TQT) studies and streamlining the development process.

Discover how AI-powered ECG quality checks enhance data reliability and operational efficiency, allowing drug developers to identify cardiac safety risks early, mitigate potential toxicity issues, and reduce the risk of late-stage failures. This semi-automated analysis minimizes human error, reduces manual labor, and supports critical decision-making throughout drug development.

Watch now to explore how combining EPQT’s high-precision assessments with AI technology can improve drug development outcomes and increase your drug candidate’s chances of success.